Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

The US Food and Drug Administration has approved Johnson & Johnson's once-daily pill for psoriasis -- a chronic skin disease.

Icotyde is an interleukin-23 (IL-23) receptor antagonist approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older.

Psoriasis is an autoimmune condition that causes rough patches of skin. The new once-daily pill has been found safe and also delivers complete skin clearance.

In the statement, J&J said that the approval will lead to a first-line systemic treatment of plaque psoriasis with a targeted oral peptide.

“Icotyde delivers something unique in psoriasis treatment – combining skin clearance with a favorable safety profile in a once‑daily pill, making it an easy addition to a patient’s routine,” said Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health.

The novel pill also aligns with the recent International Psoriasis Council guidance that suggests transitioning to systemic therapy if two cycles of topical medications applied for four weeks fail to bring meaningful improvement.

Icotyde will prove to be “a potential game‑changer for many adult and adolescent patients”, Gold said.

The FDA’s approval is based on an unprecedented body of evidence from the phase three clinical trial, which simultaneously evaluated Icotyde in adults and adolescents, and found it a safe and effective oral pill, and also better than injectables and topical creams.

According to analysts from Wall Street, Icotyde has "blockbuster potential," and the once-daily medication could capture significant market share from injectables like Skyrizi and J&J's own Tremfya, Reuters reported.

J&J is also studying the ⁠drug, chemically known as icotrokinra, for ulcerative colitis, psoriatic arthritis, and Crohn's disease.

What Is Psoriasis?

Psoriasis develops when the body makes skin cells too quickly. It causes skin cells to pile up and form visible patches or spots on the skin, which may be itchy or painful.

The condition, however, is not contagious.

According to the National Psoriasis Foundation, the skin disease affects 8 million Americans and more than 125 million people worldwide.

The condition impacts physical comfort and quality of life, especially when lesions are on visible or sensitive areas.

The plaques typically appear as raised patches with a silvery white buildup of dead skin cells or scales. They can appear anywhere on the body, although they most often appear on the scalp, knees, elbows, and torso.

Who Can Use Icotyde

Icotyde is currently approved in the US for the treatment of people with moderate-to-severe plaque. It can be used by

• adults, and pediatric patients 12 years of age and older
• who weigh at least 40 kg.

Rachel Tussey, a 47- year-old TikTok influencer from the US state of Ohio, has reportedly died following complications from the cosmetic “mommy makeover” surgery.

The “mommy makeover” tummy tuck procedure left her brain dead and was later pulled from life support, the New York Post reported.

Her death was confirmed by her husband, Jeremy Tussey, on March 18 through an update shared on a GoFundMe page created to support the family.

Rachel, with more than 27,000 TikTok followers, described herself as “over 40 & fabulous”. She had been documenting her story and her preparations, excitement, as well as her fear, ahead of the upcoming abdominoplasty procedure.

In her last video posted on the day of her surgery on February 25, she told her followers that she had “waited a really long time for” the procedure.

“I’m in good hands. I know God’s got my back. Let’s do this,” an enthusiastic Tussey dressed in a hospital gown said in the video.

While her surgery was successful, her husband was also able to speak with her briefly afterward. However, Jeremy informed his wife's followers that her face had gone pale, and later became unresponsive. Cincinnati.com reported.

Medical Neglect

In the GoFundMe page, Jeremy cited “medical neglect” that led to complications.

“Following the procedure, she suffered severe brain damage after extended loss of oxygen and was placed on a ventilator under sedation,” he said.

In his TikTok post, Jeremy told her followers that he believes the dose of painkillers given to his wife at the surgery center was too high.

“To me, it looks like incompetency. Somebody dropped the ball here,” the grieving husband said. “Somebody dropped the ball and killed my wife.”

Due to “very minimal brain activity”, on March 5, Jeremy took the “heartbreaking decision to remove her from life support”.

“Rachel was an amazing wife, mother, and person who touched so many lives. We will carry her memory with us always,” the page said.

She is survived by her husband and three children.

What Is Abdominoplasty?

The abdominoplasty, commonly referred to as a "tummy tuck", is a plastic surgery procedure that helps reduce excess skin and fat around the abdomen.

While it is not a weight loss solution, the procedure can help flatten the stomach and also tighten the abdominal muscles, and give an aesthetic look.

Plastic surgeons performed over 160,000 tummy tuck (abdominoplasty) procedures in the United States in 2022.

It is commonly preferred by:

• men and women desiring aesthetic improvement of the abdomen,
• women with significant skin and abdominal wall laxity following multiple pregnancies,
• bariatric patients who have excessive skin following significant weight loss.

However, patients undergoing the surgical procedure must have a good nutritional status, as well as optimal overall medical health.

Patients with a higher body mass index (BMI) and diabetes mellitus may be at significant risk post-surgery.

The “unprecedented” wave of meningitis outbreak in the UK's Kent, which claimed two lives, has risen to 20 cases, according to health officials.

While almost all cases have been linked to those who visited the Club Chemistry nightclub in Canterbury between March 5 and 7, a 9-month-old baby from Folkestone is reportedly battling for life in the intensive care unit.

The UK Health Security Agency (UKHSA), in a statement, noted that it is aware of a baby with confirmed Meningococcal group B infection who is not currently linked to the outbreak. The agency said it will continue to investigate the case.

The baby Nala-Rose Fletcher, from Folkestone, is currently in intensive care at Evelina London Children’s Hospital. According to doctors, she will be permanently affected by the infection, the Independent.co.uk reported.

Meanwhile, another university in the city confirmed a case of meningitis on Wednesday. The student at Canterbury Christ Church is believed to be a man who was at the nightclub and part of the 20 known cases.

“We have reached out to support the individual directly, and student wellbeing and support are reaching out and making themselves available to support fellow students more widely,” Canterbury Christ Church University said in a statement.

“We have followed UKHSA advice and informed the limited number of close contacts of the individual that they should receive precautionary antibiotics, if they have not done so already,” it added.

The Meningitis Outbreak May Have Contained

The UK health officials believe that the “unprecedented” wave of meningitis outbreak may have been “contained” as no new cluster of cases has been reported.

Health officials from the NHS, the UKHSA, and county council public health staff tackling the outbreak noted that the 20 people diagnosed with the illness have not infected anyone outside the area, the Guardian reported.

“We may have contained it. There are no cases popping up elsewhere that we know of – no cases that we know of outside the cluster – or not yet anyway,” said an official involved in the multi-agency response.

Notably, the officials have identified the outbreaks linked to a known strain of meningitis B, the report said. Six of the nine confirmed cases are group B (MenB), the agency added.

UKHSA In Prompt Action

The UKHSA has been prompt in action since the outbreak first began in Kent.

“As of 5 pm on 17 March, 9 laboratory cases are confirmed, and 11 notifications remain under investigation, bringing the total to 20. Six of the confirmed cases are confirmed to be group B meningococcal disease,” the agency said.

A 21-year-old student at the University of Kent and a teenage student at a school in the town of Faversham have died in the outbreak.

The agency has also rolled out the MenB vaccine to 5,000 students living in the University of Kent halls of residence in Canterbury.

In addition, over 2,500 doses of antibiotics -- the most effective treatment to limit the spread of invasive meningococcal disease -- has been given to students, close contacts, and others, including some of those who attended Club Chemistry between March 5 and 7.

Further, calling the illness in the Kent outbreak “severe, with rapid deterioration”, the UKHSA has issued an urgent alert to all NHS doctors in England. It advised the healthcare workers to to look for meningitis symptoms and to wear personal protective equipment before giving suspected patients antibiotics.

What is Meningococcal disease?

Caused by meningococcal bacteria, the meningococcal disease leads to inflammation of the lining of the brain also called as meningitis. The condition can also lead to sepsis or blood poisoning.

As the onset can be sudden, knowing the signs and symptoms and acting quickly is important.

Common symptoms include:

• rash
• sudden onset of high fever
• severe and worsening headache
• vomiting and diarrhoea
• joint and muscle pain
• seizures